On June 21, 2023 Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, reported the presentation of compelling preclinical data at the Cellicon Valley 2023 Meeting in Philadelphia, PA (Press release, Interius BioTherapeutics, JUN 21, 2023, View Source [SID1234632824]). The data demonstrates the potential of Interius Bio’s lead program (INT2104) to generate biologically active CAR cells directly in vivo for the treatment of B-cell malignancies. The company will also be unveiling non-human primate data from multiple studies at the In Vivo Engineering of Therapeutic Cells Summit in Boston, MA on July 10-12, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In mouse models of systemic lymphoma, complete tumor clearance occurs across a wide dose range after a single intravenous infusion of Interius Bio’s targeted cell-specific lentiviral vector. The proprietary vector mediates direct in vivo creation of CAR T and NK cells that specifically kill malignant B cells. In non-human primates treated with a single vector infusion in the absence of conditioning chemotherapy, significant B cell depletion is observed with no toxicity and has been sustained in one animal for over 6 months.
Interius President and CEO Phil Johnson, MD states "The company’s preclinical data address three critical questions: Does it work? Can you make it? Is it safe? We are thrilled that the answer to each of these questions is yes based on extensive animal model work, including dosing of over 20 cynomolgus macaques, with a vector dose equivalent or exceeding the highest proposed human dose. In all models we have observed no signs of cytokine release syndrome (CRS) or neurotoxicity, no clinical symptoms, and no laboratory abnormalities."
"The compelling preclinical findings of specificity, biologic effect, tolerability and pharmacologic profile in multiple animal models following intravenous administration support the advancement of INT2104 to the clinic as a promising treatment option for B-cell malignancies," says Tim Culp, PhD, VP of Research and Development. "We continue to maintain our timeline to IND with initial human data expected in 2024."